- Disease progression, deterioration of performance status, and neuropathy are associated with worsened QoL in patients with advanced gastric cancer receiving ramucirumab with or without paclitaxel vs placebo.
Why this matters
- Controlling disease should be a primary objective for clinical care.
- Pooled analysis of the phase 3 RAINBOW and REGARD clinical trials of ramucirumab with or without paclitaxel vs placebo in 989 patients with previously treated gastric or gastroesophageal junction cancer.
- QoL was assessed at from baseline to week 6 by the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30.
- Funding: Eli Lilly and Company.
- Disease progression (vs complete or partial disease) as the best overall response (detected radiologically) was associated with worse QoL on global QoL (P=.0011), all functional scales (physical, role, emotional, cognitive, and social scales; P<.0001 to p=".0306)," and symptom scales nausea pain appetite loss>
- Worsening of performance status showed similar associations with worse QoL.
- Neuropathy as an investigator-reported treatment emergent adverse event was associated with worsening QoL on physical, role, emotional, social function scales and on 1 symptom scale (appetite loss), based on ANOVA P<.05.>
- Excludes patients with disease progression before week 6.